Zobrazeno 1 - 7
of 7
pro vyhledávání: '"R. F. Patientia"'
Autor:
Jeffrey Hafkin, Florian von Groote-Bidlingmaier, Rajesh Gupta, Ebrahim Variava, Patricia Segura, Victor Lizarbe, Virgaine Bielskiene, Suzanne Staples, Janice Campos Caoili, Manfrid Danilovits, Elizabeth Cadena, Andra Cirule, Liliana Domente, R. F. Patientia, Epifanio Sanchez, Edita Davidaviciene, Norbert Hittel, Charles D. Wells, Carolyn Petersen, Vincent Balanag, Eduardo Ticona, Charles Yu, Lawrence Geiter
Publikováno v:
The Lancet Respiratory Medicine. 7:249-259
Summary Background Delamanid is one of two recently approved drugs for the treatment of multidrug-resistant tuberculosis. We aimed to evaluate the safety and efficacy of delamanid in the first 6 months of treatment. Methods This randomised, double-bl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b56b1ef548c17732ebd97e745ca2574
https://doi.org/10.1016/s2213-2600(18)30426-0
https://doi.org/10.1016/s2213-2600(18)30426-0
Autor:
Kathleen D. Eisenach, Eduardo Gotuzzo, Pawandeep Kaur, Nancy Dianis, Bruno Martel, Carlos Seas, Andreas H. Diacon, Florian von Groote-Bidlingmaier, Leonid Lecca, Patrick P. J. Phillips, R. F. Patientia, Charles A. Peloquin, Carole D. Mitnick, Dante Vargas, C. Robert Horsburgh, Antonio Moreno-Martinez, Kathleen Robergeau Hunt, Juan Santillan, Neel R. Gandhi, Donna Butler
Publikováno v:
Antimicrobial agents and chemotherapy, vol 62, iss 10
Patients with multidrug-resistant tuberculosis in Peru and South Africa were randomized to a weight-banded nominal dose of 11, 14, 17, or 20 mg/kg/day levofloxacin (minimum, 750 mg) in combination with other second-line agents. A total of 101 patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d13bce5150aac21f1a23b80448fa374
https://hdl.handle.net/20.500.12866/4096
https://hdl.handle.net/20.500.12866/4096
Autor:
Eduardo Gotuzzo, Bruno Martel, R. F. Patientia, Florian von Groote-Bidlingmaier, Kathleen D. Eisenach, Nancy Dianis, Carlos Seas, Andreas H. Diacon, Charles A. Peloquin, Patrick P. J. Phillips, Carole D. Mitnick, Antonio Moreno-Martinez, Donna Butler, Neel R. Gandhi, Leonid Lecca, Juan Santillan, Dante Vargas, Kathleen Robergeau Hunt, C. Robert Horsburgh, Tara C. Bouton
Publikováno v:
Trials
Trials, vol 18, iss 1
Trials, Vol 18, Iss 1, Pp 1-8 (2017)
Trials, vol 18, iss 1
Trials, Vol 18, Iss 1, Pp 1-8 (2017)
Background Current guidelines for treatment of multidrug-resistant tuberculosis (MDR-TB) are largely based on expert opinion and observational data. Fluoroquinolones remain an essential part of MDR-TB treatment, but the optimal dose of fluoroquinolon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1adb2601e5535fd8bc302ba238864a56
http://europepmc.org/articles/PMC5702225
http://europepmc.org/articles/PMC5702225
Autor:
Liesl Page-Shipp, Jenny Allen, Paul Meyvisch, Karel de Beule, Alexander S. Pym, Rene Krause, Andreas H. Diacon, Johan Verbeeck, Koen Andries, Martin P. Grobusch, Roxana Rustomjee, Nacer Lounis, Rolf van Heeswijk, R. F. Patientia, Juan Carlos Palomino, Christoffel Pistorius, Amour Venter, David F Mc Neeley, Tine De Marez, Wim Parys, Gavin J. Churchyard, Mampedi Bogoshi
Publikováno v:
The New England journal of medicine
New England journal of medicine, 360(23), 2397-2405. Massachussetts Medical Society
New England journal of medicine, 360(23), 2397-2405. Massachussetts Medical Society
Background The diarylquinoline TMC207 offers a new mechanism of antituberculosis action by inhibiting mycobacterial ATP synthase. TMC207 potently inhibits drug-sensitive and drug-resistant Mycobacterium tuberculosis in vitro and shows bactericidal ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e7fd46492791165c17beb0aa69bbb7a
https://doi.org/10.1056/nejmoa0808427
https://doi.org/10.1056/nejmoa0808427
Autor:
T. De Marez, C. Reddy, R. F. Patientia, Andreas H. Diacon, Peter R. Donald, J. Allen, K. De Beule, D. F. McNeeley, Thuli Mthiyane, R. Kerstens, Roxana Rustomjee, Anil Koul, Venter A, R. van Heeswijk
Publikováno v:
Antimicrobial Agents and Chemotherapy. 52:2831-2835
Tibotec Medicinal Compound 207 (TMC207) is a novel diarylquinoline with a unique mode of action that targets mycobacterial ATP synthase. TMC207 exhibits high in vitro activity against mycobacterial strains either susceptible or resistant to all first
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69dccd7862365e5b63fe8605a5415070
https://doi.org/10.1128/aac.01204-07
https://doi.org/10.1128/aac.01204-07
Autor:
R. Mahanyele, Koen Andries, T. De Marez, N. Bantubani, Alexander Pym, Peter R. Donald, Martin P. Grobusch, R. Narasimooloo, D. F. McNeeley, Nacer Lounis, Andreas H. Diacon, R. F. Patientia, R. van Heeswijk, P. Meyvisch
Publikováno v:
Antimicrobial agents and chemotherapy
Antimicrobial agents and chemotherapy, 56(6), 3271-3276. American Society for Microbiology
Antimicrobial agents and chemotherapy, 56(6), 3271-3276. American Society for Microbiology
The 2-year follow-up results for a randomized placebo-controlled study of 47 patients with multidrug-resistant pulmonary tuberculosis treated with either the new diarylquinoline TMC207, recently renamed bedaquiline, or placebo, added to the first 8 w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d232e540e91fdc9e937d6f2ec0cf503e
https://hdl.handle.net/10067/1025770151162165141
https://hdl.handle.net/10067/1025770151162165141
Autor:
Andreas H. Diacon, P. J. Smith, P. D. van Helden, Peter R. Donald, Helen McIlleron, R. F. Patientia, Venter A, J. S. Maritz
We studied the early bactericidal activity of twice the standard dose of rifampin in subjects with pulmonary tuberculosis evidenced by positive smears. The observed mean 2-day activity was almost double that reported at the standard dose. Further stu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecce3b630940fa9346c9318904948e6c
https://europepmc.org/articles/PMC1932511/
https://europepmc.org/articles/PMC1932511/